Multicentre evaluation of 5B9, a monoclonal anti‐PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology

Abstract

BackgroundFunctional tests for the diagnosis of heparin‐induced thrombocytopenia (HIT) exhibit variable performance. ObjectivesWe evaluated in a multicenter study whether 5B9, a monoclonal anti‐PF4/heparin IgG mimicking human HIT antibodies, could be used as an internal quality control. Methods5B9 was sent to 11 laboratories in seven countries, and six initial concentrations ranging from 10 to 400 μg/mL were tested by heparin‐induced platelet activation assay (HIPA), serotonin release assay (SRA), platelet aggregation test (PAT), flow cytometry (FC), or heparin‐induced multiple‐electrode aggregometry (HIMEA). Each method was evaluated in three different laboratories using experimental procedures identical to those usually applied for the diagnosis of HIT by testing platelets from 10 different healthy donors. ResultsThe procedures used varied among the laboratories, particularly when platelet‐rich plasma and whole blood were used. Nevertheless, positive results were obtained with at least 100 μg/ml of 5B9 for most donors tested by all centers (except one) performing HIPA, SRA, or HIMEA. FC and PAT results were more heterogeneous. FC results from one center that used washed platelets preincubated with PF4 were positive with all donors at 50 µg/ml 5B9, but at least 200 μg/ml of 5B9 were required to activate cells with most donors tested using PAT. ConclusionThis study confirms that HIT functional tests are not well standardized and exhibit variable sensitivity for the detection of platelet‐activating antibodies. However, 5B9 is a potentially useful tool to standardize functional tests, to select responding platelet donors, and consequently to improve the performance of these assays and comparability between laboratories.